{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-016238","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.127833+00:00","generated_at":"2026-05-15T16:49:33.712388+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ADC Therapeutics posts Q4 revenue $22.3M; net loss narrows; LOTIS-5 topline data expected Q2 2026","bullets":["Q4 net product revenue $22.3M, full year $73.6M, up from $16.4M and $69.3M respectively in 2024.","Q4 net loss $6.4M ($0.04/share) vs $30.7M ($0.29/share) in 2024; adjusted net loss $13.5M.","Cash and cash equivalents $261.3M; expected cash runway at least into 2028.","LOTIS-5 Phase 3 topline data in 2L+ DLBCL expected Q2 2026; LOTIS-7 full data by year-end 2026.","Amendment to HealthCare Royalty financing reduces change-of-control payment to $150M through 2027; warrants for 9.8M shares at $3.81."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-016238","json":"https://secwatch.observer/filing/0001628280-26-016238.json","markdown":"https://secwatch.observer/filing/0001628280-26-016238.md","text":"https://secwatch.observer/filing/0001628280-26-016238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000162828026016238/0001628280-26-016238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000162828026016238/adc-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:49:33.712388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}